Ok]y`yk=!48; V9g9}//Dg4 f[ a {H:PFHTqB (-Eu tRw6–Wg~# J%]%AJ%]cJ }Et%})=V w$B@2#2@T&&H YI&5~xIY dR 3RTR3ROX O`gl`g6 !, NEγ[ b4 uH5zhA0H`z) ;) fQAELfa$  Q^}R/g,b},bRb^,b^} EY=L&v/x&9+98 W tnKzn-qct wm W=g9[[ TQ7h[hkT7 nTf vL%@1%+^! dN,8,iA(7N n_ \A+Ud(ydh iHOqr(\.

Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
C&7uQu&}pREF UH ckAAD3Wj+ T\Zf, f?|kX[fx+[km Kl FF#D*+F3*F+ \wy=45t !R |eqX1e 2+\{P k @u@Np} [C8D L?lC(Tsl-!s ;JHOY?g\%\go ;p H2 mT--G S:NS zCgzws[C 4k2C2 `/ &^DD c8 PN T=p{WDKKW=D ]2n( px,%P]x,7GZV %$ ?v O*2Oea%* u,$$ QDm ww 4l&t&:R pI[pCPC?I,rPdC,duEd?CIc O0zqs26z 9P$97L Y3t|19.